Zirconium-89 patritumab deruxtecan - Daiichi Sankyo Company
Alternative Names: 89Zr-Patritumab deruxtecan - Daiichi Sankyo CompanyLatest Information Update: 09 Feb 2024
At a glance
- Originator Daiichi Sankyo Company
- Class Drug conjugates; Immunoconjugates; Monoclonal antibody diagnostics; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 24 Jan 2024 Preclinical trials in Non-small cell lung cancer (Diagnosis) in Japan (IV).
- 24 Jan 2024 Daiichi Sankyo Company plans a phase II trial for Non-small cell lung cancer (Diagnosis) in Japan (IV) (NCT06222489)